TY - JOUR
T1 - The pharmacokinetics of nelfinavir in HIV-1-infected children
AU - van Heeswijk, Rolf P. G.
AU - Scherpbier, Henriëtte J.
AU - de Koning, Linda A.
AU - Heymans, Hugo S. A.
AU - Lange, Joep M. A.
AU - Beijnen, Jos H.
AU - Hoetelmans, Richard M. W.
PY - 2002
Y1 - 2002
N2 - The authors investigated the steady-state plasma pharmacokinetics of nelfinavir in HIV-1-infected children in a dosage of 30 mg/kg every 8 hours and 45 mg/kg every 12 hours in 12 HIV-1-infected children (aged 2.1 to 10.8 years) participating in an open-label study of nelfinavir in combination with stavudine and lamivudine. Median values of the primary pharmacokinetic parameters of nelfinavir 30 mg/kg every-8-hours (n = 8) and 45 mg/kg every 12 hours (n = 10) were, respectively, for the area under the plasma concentration-time curve over 24 hours, 90.5 and 71.9 h.mug/mL, for the trough concentration 1.9 and 1.0 mug/mL, and for the maximal concentration 6.3 and 5.2 mug/mL. Overall, a 7-fold interpatient variability was observed for the exposure to nelfinavir. Nelfinavir 30 mg/kg every-8-hours or 45 mg/kg every 12 hours in HIV-1-infected children generally resulted in plasma concentrations higher than those obtained in adults. However, due to a large interpatient variability in the exposure, individual dosage adjustments based on plasma concentrations may be necessary for both dosing regimens to ensure optimal treatment
AB - The authors investigated the steady-state plasma pharmacokinetics of nelfinavir in HIV-1-infected children in a dosage of 30 mg/kg every 8 hours and 45 mg/kg every 12 hours in 12 HIV-1-infected children (aged 2.1 to 10.8 years) participating in an open-label study of nelfinavir in combination with stavudine and lamivudine. Median values of the primary pharmacokinetic parameters of nelfinavir 30 mg/kg every-8-hours (n = 8) and 45 mg/kg every 12 hours (n = 10) were, respectively, for the area under the plasma concentration-time curve over 24 hours, 90.5 and 71.9 h.mug/mL, for the trough concentration 1.9 and 1.0 mug/mL, and for the maximal concentration 6.3 and 5.2 mug/mL. Overall, a 7-fold interpatient variability was observed for the exposure to nelfinavir. Nelfinavir 30 mg/kg every-8-hours or 45 mg/kg every 12 hours in HIV-1-infected children generally resulted in plasma concentrations higher than those obtained in adults. However, due to a large interpatient variability in the exposure, individual dosage adjustments based on plasma concentrations may be necessary for both dosing regimens to ensure optimal treatment
U2 - https://doi.org/10.1097/00007691-200208000-00004
DO - https://doi.org/10.1097/00007691-200208000-00004
M3 - Article
C2 - 12142631
SN - 0163-4356
VL - 24
SP - 487
EP - 491
JO - Therapeutic drug monitoring
JF - Therapeutic drug monitoring
IS - 4
ER -